Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy

Rodrigo Schwartz; Genevieve Ho; Andrea L. Smith; Helena Collgros; Amanda Pereira; Bruna Melhoranse Gouveia; Georgina V. Long; Alexander M. Menzies; Alison J. Potter; Elizabeth C. Paver; Phoebe Star; Richard A Scolyer; Linda K. Martin

doi:10.1111/jdv.17940

Back

Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy

Letter 2022 en

Abstract

1 min read

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2024

30 Years of Semiconductor Nanowire Research: A Personal Journey

Peidong Yang

Letter2024

The effect of age on the severity of psoriasis

Shir Azrielant, Su M. Lwin, Christopher Em Griffiths

Letter2024

Association of atopic dermatitis with depression and sleep quality in an Asian general population cohort of 8887 participants

Yik Weng Yew, Bill Rong Qin Chang, Theresia Mina, Elio Riboli, Eng Sing Lee, Joanne Ngeow, Paul Elliott, John C. Chambers, Jimmy Lee, Marie Loh

Article2025

No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

Sueh‐li Lim, Cameron Wellard, Rajeev Rajagopal, Simon J. Harrison, Amit Khot, Hang Quach, P. Joy Ho, Elizabeth S. Moore, Erica M. Wood, Andrew Spencer

Article2022

Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The <scp>ELIXA</scp> trial

Hertzel C. Gerstein, Emil Wolsk, Brian Claggett, Rafael Díaz, Kenneth Dickstein, Sibylle Hess, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer